Vanguard Group’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-8,240,391
| Closed | -$28M | – | 4179 |
|
|
2018
Q3 | $28M | Buy |
8,240,391
+194,437
| +2% | +$701K | ﹤0.01% | 2421 |
|
|
2018
Q2 | $30.3M | Buy |
8,045,954
+278,315
| +4% | +$1.36M | ﹤0.01% | 2377 |
|
|
2018
Q1 | $31.8M | Sell |
7,767,639
-126,220
| -2% | -$588K | ﹤0.01% | 2311 |
|
|
2017
Q4 | $36.7M | Buy |
7,893,859
+328,889
| +4% | +$1.81M | ﹤0.01% | 2224 |
|
|
2017
Q3 | $53.7M | Buy |
7,564,970
+366,701
| +5% | +$2.64M | ﹤0.01% | 2009 |
|
|
2017
Q2 | $52M | Buy |
7,198,269
+349,521
| +5% | +$2.18M | ﹤0.01% | 1998 |
|
|
2017
Q1 | $42.2M | Buy |
6,848,748
+302,986
| +5% | +$1.66M | ﹤0.01% | 2090 |
|
|
2016
Q4 | $38.4M | Buy |
6,545,762
+146,770
| +2% | +$802K | ﹤0.01% | 2104 |
|
|
2016
Q3 | $34M | Buy |
6,398,992
+197,290
| +3% | +$1.06M | ﹤0.01% | 2113 |
|
|
2016
Q2 | $41.1M | Sell |
6,201,702
-125
| -0% | -$699 | ﹤0.01% | 1991 |
|
|
2016
Q1 | $29M | Buy |
6,201,827
+199,730
| +3% | +$797K | ﹤0.01% | 2125 |
|
|
2015
Q4 | $30.3M | Sell |
6,002,097
-1,112,591
| -16% | -$5.29M | ﹤0.01% | 2124 |
|
|
2015
Q3 | $25M | Buy |
7,114,688
+245,837
| +4% | +$1.65M | ﹤0.01% | 2187 |
|
|
2015
Q2 | $68.6M | Buy |
6,868,851
+336,631
| +5% | +$3.61M | ﹤0.01% | 1765 |
|
|
2015
Q1 | $83.2M | Buy |
6,532,220
+841,982
| +15% | +$10.8M | 0.01% | 1625 |
|
|
2014
Q4 | $80.5M | Buy |
5,690,238
+99,499
| +2% | +$1.54M | 0.01% | 1559 |
|
|
2014
Q3 | $76.9M | Buy |
5,590,739
+1,430,465
| +34% | +$21.9M | 0.01% | 1542 |
|
|
2014
Q2 | $64M | Buy |
4,160,274
+40,094
| +1% | +$568K | 0.01% | 1707 |
|
|
2014
Q1 | $70.2M | Buy |
4,120,180
+1,658,084
| +67% | +$25M | 0.01% | 1598 |
|
|
2013
Q4 | $31.9M | Buy |
2,462,096
+167,368
| +7% | +$2M | ﹤0.01% | 1993 |
|
|
2013
Q3 | $23.2M | Buy |
2,294,728
+32,955
| +1% | +$293K | ﹤0.01% | 2060 |
|
|
2013
Q2 | $16.9M | Buy |
+2,261,773
| New | +$17.7M | ﹤0.01% | 2126 |
|
Vanguard Group's KERX Position: Q4 2018 in Review
Vanguard Group sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 8,240,391 shares — an estimated $28M sold.
Vanguard Group first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $83.2M in Q1 2015. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Vanguard Group reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Vanguard Group sold 8,240,391 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $28M.
- Vanguard Group first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Vanguard Group's Keryx Biopharmaceuticals Inc position peaked at $83.2M in Q1 2015.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Vanguard Group's 13F filing for Q4 2018, filed 14 Feb 2019.